

Cifurtilimab

Cat. No.:	HY-P99603
CAS No.:	1629760-27-5
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Cifurtilimab (SEA-CD40) is an agonistic nonfucosylated, human IgG1 monoclonal antibody directed against CD40. Cifurtilimab shows antitumor activities ^{[1][2]} .
IC₅₀ & Target	CD40 ^[1]
In Vitro	Cifurtilimab has enhanced FcγRIIIa binding (~10x greater than parent IgG1 antibody) that drives increased effector function, resulting in more potent immune stimulatory activity than antibodies with muted or selective FcγR binding ^[1] . Cifurtilimab exposure results in a distinct signature of responses including activation of APCs, CD8+ and CD4+ T cells and NK cells, and targeted depletion of CD40+ B cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	In preclinical mouse models, Cifurtilimab combined with chemotherapeutic agents to drive robust anti-tumor activity ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Neff-LaFord H, et al. SEA-CD40 is a non-fucosylated anti-CD40 antibody with potent pharmacodynamic activity in preclinical models and patients with advanced solid tumors. *Cancer Research*, 2020, 80(16_Supplement): 5535-5535.

[2]. Zeng W, et al. 438 Synergy between SEA-CD40 and chemotherapeutics drives curative antitumor activity in preclinical models. 2020.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA